The clinical trial investigates the efficacy of LUT014 in treating acneiform rashes, a common and debilitating side effect for patients undergoing treatment with EGFR inhibitors. These drugs, while effective at targeting cancer cell proliferation, often damage healthy skin tissue by suppressing the MAPK pathway. LUT014 functions as a B-Raf inhibitor that utilizes a paradoxical reactivation mechanism to protect skin cells without interfering with the systemic anti-cancer activity of the primary therapy.
Lutris Pharma to Present Phase 2 Data on LUT014 Acneiform Rash Treatment
Lutris Pharma is set to unveil updated findings from its phase 2 trial of LUT014, a topical gel designed to mitigate skin toxicities triggered by anti-cancer therapies. The results will be presented on October 2 at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria.
Dr. Anisha Patel of The University of Texas MD Anderson Cancer Center will lead the presentation, titled "Acneiform Rash from EGFR Inhibitor Therapy: Durable, Mechanism-Directed Reduction with Topical LUT014." The session, scheduled for 11:25 am CET in Hall N, marks a significant milestone for the Tel Aviv-based biopharmaceutical firm. Previous data from the study indicated that the gel offers a favorable safety profile and clinical benefits for patients with metastatic colorectal cancer, potentially improving long-term adherence to essential oncology regimens.
Comments (0)
No comments yet. Be the first!